NEWS
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader
Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors
NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid
Press Release: Rarecells announces Appointment of New Director to the Board
NEW YORK, Sept. 6, 2022 /PRNewswire/ — Rarecells, Inc. today announced the appointment of Dr. Neil Gunn,
Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
NEW YORK and PARIS, Dec. 9, 2021 — Rarecells, Inc., an innovative Liquid Biopsy
Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
New York, November 9th, 2021 — Rarecells, Inc., a healthcare company in the field
Prof. Patrizia Paterlini-Brechot – Rarecells, Inc. – embarks on the search for the First Cell to beat cancer
We are delighted to join the prestigious The Oncology Think Tank, initiated by Prof. Azra
Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS
PARIS, April 6, 2021 /PRNewswire/ — Rarecells Inc., a leading Liquid Biopsy company is pleased to
Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
We are enthusiastic to share the results of the Professor Karin Ried and researchers of
2nd Liquid Biopsies Congress – Global Exchange
Attend the Keynote presentation ”New non-invasive approaches for early diagnosis and follow up of